About Poseida Therapeutics
Poseida Therapeutics is a Healthcare company based in San Diego (United States) founded in 2015, and was acquired by Roche in November 2024. Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies. Poseida Therapeutics has raised $323.78 million across 6 funding rounds from investors including Fidelity Investments, Roche and Novartis. The company has 259 employees. Poseida Therapeutics offers products and services including piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline. Its focus areas include Life Sciences, Cell Therapy, Adoptive Cell Therapy and T-Cell. Its legal entity is POSEIDA THERAPEUTICS, INC. Its competitors include Celgene, Denali Therapeutics and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Poseida Therapeutics was founded in 2015 and is based in San Diego, United States. Operations focus on the biotechnology sector, where CAR-T and gene therapy products are developed for cancer and orphan liver diseases. Genome engineering is applied to silence target genes or insert therapeutic ones. Proprietary tools such as the piggyBac DNA Modification System, CRISPR, TALEN, and Footprint-Free Gene Editing System are utilized for precise, synthetic, and virus-free modifications.
- Headquarters San Diego, United States
- Employees 259
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website poseida.com
- Social LinkedIn X
- Acquired by Roche (Nov 2024)
- Legal Name Poseida Therapeutics, Inc.
- Annual Revenue$64.7 M (USD)-50as on Dec 31, 2023
- Net Profit-$123.43 M (USD)-93as on Dec 31, 2023
- EBITDA-$129.5 M (USD)-116as on Dec 31, 2023
- Total Equity Funding$323.78M (USD)
in 6 rounds
- Latest Funding Round$50M (USD), Post-IPO
Aug 2023
- InvestorsFidelity Investments
& 14 more
- Employee Count259
- Acquired byRoche
(Nov 2024)
Products & Services of Poseida Therapeutics
Poseida Therapeutics offers a comprehensive portfolio of products and services, including piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline.
Inserts large genetic payloads into genomes for therapy development.
Enables accurate edits in cell types for cancer and disease treatments.
Develops allogeneic therapies for relapsed multiple myeloma and cancers.
Funding Insights of Poseida Therapeutics
Poseida Therapeutics has successfully raised a total of $323.78M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $323.78M
- Total Rounds 6
- Last Round Post-IPO — $50M
- First Round $30M
(Dec 2015)
- Investors Count 14
All 6 funding rounds of Poseida Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $50M | Post-IPO | – | – | |
| Jun 2020 | $110M | Series D | – | Fidelity Investments | |
| Apr 2019 | $142.12M | Series C | – | Novartis | |
| Apr 2018 | $30.5M | Series B | – | Longitude Capital | |
| Aug 2017 | $11.16M | Series A | – | – | – |
| Dec 2015 | $30M | Series A | – | Malin PLC | – |
15 investors in total: 15 institutional.
Investors in Poseida Therapeutics
Poseida Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Roche and Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Rapha Capital Management is engaged in identifying and investing in biopharmaceutical companies. | 2018 | raphacap.com | Surfside, United States | |
Web application services requiring JavaScript, along with potential agricultural-related offerings. | schonfeld.com | |||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Pentwater Capital Management is engaged in event driven investment strategies. | 2007 | pwcm.com | Naples, USA | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Tavistock Group is engaged in global diversified investments. | tavistock.com | |||
Generic pharmaceuticals are developed, manufactured, and marketed worldwide. | 1923 | astellas.com | Chiba, Japan |
Investor details for Poseida Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Poseida Therapeutics
39 people are tracked at Poseida Therapeutics (13 in leadership, 13 in board & advisors, 13 in team); the tracked headcount is 259.
| Name | Role | Group |
|---|---|---|
Cierra Grenon | Associate Director, Accounting | Leadership |
Melissa Simonsen | Senior Director, Talent Acquisition | Leadership |
Carol Susla | Vice President Quality | Leadership |
Laura Fuchs | Senior Director Quality Assurance | Leadership |
Shannon Fernbaugh | Sr. Director, Quality Control | Leadership |
Ryan Koed | Associate Director QA | Leadership |
Tracey Ashcraft | Executive Director, Financial Planning & Analysis | Leadership |
Patrick Hong | Director, Gene Engineering | Leadership |
Melissa Johns | Director, Financial Planning And Analysis | Leadership |
Jeffrey W. Winkelman | VP, Intellectual Property | Leadership |
Lisa Alcamo Portale Rac | Senior Vice President Regulatory Affairs | Leadership |
Shane Dotson | Senior Director Of Accounting | Leadership |
Sherry Wiffen | Senior Director, Human Resources | Leadership |
Luke Corning | Board Member | Board & advisors |
Kathryn A. Whitehead | Scientific Advisor | Board & advisors |
Mark A. Kay | Scientific Advisor | Board & advisors |
Ian E. Alexander | Scientific Advisor | Board & advisors |
Julian Grünewald | Scientific Advisor | Board & advisors |
Carl June | Scientific Advisor | Board & advisors |
George M. Church | Scientific Advisor | Board & advisors |
19 more people are available in the full profile.
Complete people profiles for Poseida Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Poseida Therapeutics
5 dated milestones of Poseida Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Poseida Therapeutics is founded.
- Funding First funding round of $30.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $50.0M.
- Exit Acquired by Roche.
Competitors of Poseida Therapeutics
Poseida Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Celgene, Denali Therapeutics and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| celgene.com | 1986 | Summit, United States | $45M | 4,891 | Therapies for cancer and inflammatory diseases are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Poseida Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Poseida Therapeutics
The website of Poseida Therapeutics (poseida.com) receives about 4.5K visits a month and ranks #3,177,072 among all websites worldwide, #4,184 in Biotechnology and Pharmaceuticals.
- Monthly visits4.5K
▼ 19.1% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,177,072
among all websites
- Category rank#4,184
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.2
- Average visit1 min 21 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Poseida Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| daiichisankyo.com | 100% | 72.3K | #682,883 | View details | |
| roche.com | 84% | 1.3M | #42,219 | View details | |
urotoday.com | urotoday.com | 50% | #260,951 | – |
Top companies in Cell Therapy
3 companies that operate in the same segment as Poseida Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Poseida Therapeutics
Complete news archive for Poseida Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Poseida Therapeutics
Poseida Therapeutics was founded in 2015.
Poseida Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Poseida Therapeutics is a funded company, having raised a total of $323.78M across 6 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Dec 2015.
Poseida Therapeutics has 259 employees.
Annual revenue of Poseida Therapeutics is $64.7M as on Dec 31, 2023.
Poseida Therapeutics was founded in 2015 and is based in San Diego, United States. Operations focus on the biotechnology sector, where CAR-T and gene therapy products are developed for cancer and orphan liver diseases. Genome engineering is applied to silence target genes or insert therapeutic ones. Proprietary tools such as the piggyBac DNA Modification System, CRISPR, TALEN, and Footprint-Free Gene Editing System are utilized for precise, synthetic, and virus-free modifications.
Poseida Therapeutics's top competitors include Denali Therapeutics, MiRagen and Celgene.
Poseida Therapeutics offers piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, and CAR-T Therapy Pipeline.
Poseida Therapeutics has 15 investors. Key investors include Fidelity Investments, Roche, Novartis, Astellas Pharma, and Perceptive Advisors.
Poseida Therapeutics operates through Poseida Therapeutics, Inc..
Yes. Poseida Therapeutics was acquired by Roche in November 2024.